Table 1.
Patient demographic and clinical characteristics.
| Variables | N (%) | Non-PMRT (%) | PMRT (%) | P |
|---|---|---|---|---|
| Age (years) | ||||
| ≤50 | 336 (73.0) | 129 (69.4) | 207 (75.5) | 0.142 |
| >50 | 124 (27.0) | 57 (30.6) | 67 (24.5) | |
| Race/ethnicity | ||||
| Non-hispanic white | 265 (57.6) | 113 (60.8) | 152 (55.5) | 0.487 |
| Non-hispanic black | 93 (20.2) | 34 (18.3) | 59 (21.5) | |
| Hispanic | 64 (13.9) | 27 (14.5) | 37 (13.5) | |
| Other | 38 (8.3) | 12 (6.5) | 26 (9.5) | |
| Grade | ||||
| Well/moderately differentiated | 28 (6.1) | 7 (3.8) | 21 (7.7) | 0.159 |
| Poorly differentiated/undifferentiated | 374 (81.3) | 152 (81.7) | 222 (81.0) | |
| Unknown | 58 (12.6) | 27 (14.5) | 31 (11.3) | |
| Tumor stage | ||||
| T1 | 20 (4.3) | 11 (5.9) | 9 (3.3) | 0.002 |
| T2 | 131 (28.5) | 69 (37.1) | 62 (22.6) | |
| T3 | 201 (43.7) | 68 (36.6) | 133 (48.5) | |
| T4 | 108 (23.5) | 38 (20.4) | 70 (25.5) | |
| Nodal stage | ||||
| N0 | 171 (37.2) | 60 (32.3) | 111 (40.5) | 0.129 |
| N1 | 199 (43.3) | 92 (49.5) | 107 (39.1) | |
| N2 | 59 (12.8) | 24 (12.9) | 35 (12.8) | |
| N3 | 31 (6.7) | 10 (5.4) | 21 (7.7) | |
| Risk stratification | ||||
| Intermediate risk | 233 (50.7) | 111 (59.7) | 122 (44.5) | 0.001 |
| High risk | 227 (49.3) | 75 (41.3) | 152 (55.5) | |
| ER status | ||||
| Negative | 358 (78.8) | 142 (76.3) | 216 (78.8) | 0.662 |
| Positive | 84 (18.3) | 35 (18.8) | 49 (17.9) | |
| Unknown | 18 (3.9) | 9 (4.8) | 9 (3.3) | |
| PR status | ||||
| Negative | 389 (84.6) | 156 (83.9) | 233 (85) | 0.904 |
| Positive | 51 (11.1) | 21 (11.3) | 30 (10.9) | |
| Unknown | 20 (4.3) | 9 (4.8) | 11 (4.0) | |
| HER-2 status (n = 213) | ||||
| Negative | 196 (92) | 73 (93.6) | 123 (91.1) | 0.348 |
| Positive | 17 (8) | 5 (6.4) | 12 (8.9) | |
ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; PMRT, post-mastectomy radiotherapy; PR, progesterone receptor.